- Home
- TWIN vs ABOS Comparison
TWIN vs ABOS Comparison
Compare TWIN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWIN | ABOS |
|---|---|---|
| Founded | 1918 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TWIN | ABOS |
|---|---|---|
| Price | $16.79 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $12.00 | $7.67 |
| AVG Volume (30 Days) | 29.3K | ★ 163.1K |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $347,837,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $696.98 | ★ N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $6.16 | $0.86 |
| 52 Week High | $17.30 | $2.46 |
Technical Indicators
Market Signals| Indicator | TWIN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 49.33 |
| Support Level | $15.06 | $2.01 |
| Resistance Level | $18.00 | $2.39 |
| Average True Range (ATR) | 0.55 | 0.14 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 58.84 | 25.54 |
Price Performance
Historical ComparisonAbout TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.